<ul><li>BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival<br></li><li>UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy<br></li><li>Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates<br></li></ul>

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

Episode#9 Mar 03th 2026: BioNTech's Lean ADC Trial,

A fast paced, AI-generated podcast on pharma and biotech news.

Share Episode#9 Mar 03th 2026: BioNTech's Lean ADC Trial,

Sign up to save your podcasts

Episode#9 Mar 03th 2026: BioNTech's Lean ADC Trial,

Episode#9 Mar 03th 2026: BioNTech's Lean ADC Trial,